Drugs for Narcolepsy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 34)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
2 |
|
Sodium oxybate |
Approved |
Phase 4 |
|
502-85-2 |
23663870 |
Synonyms:
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT
NSC-84223
OXYBATE SODIUM
SODIUM OXYBATE
|
SODIUM OXYBUTYRATE
WY-3478
XYREM
|
|
3 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
4 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
5 |
|
Anesthetics |
|
Phase 4 |
|
|
|
6 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
7 |
|
Modafinil |
Approved, Investigational |
Phase 3 |
|
68693-11-8 |
4236 |
Synonyms:
2-((Diphenylmethyl)sulfinyl)acetamide
2-((R)-(Diphenylmethyl)sulfinyl)acetamide
2-[(Diphenylmethyl)sulphinyl]acetamide
Alertec
Armodafinil
Benzhydrylsulfinylacetamide
CEP-1538
CEPA brand OF modafinil
Cephalon brand OF modafinil
Cephalon brand OF modafinil, reformulated
CRC-40476
CRL-40476
Dea No. 1680
DEP-1538
Draxis brand OF modafinil
Lafon brand OF modafinil
Merckle brand OF modafinil
Modafinil
|
Modafinil [Usan:Inn]
MODAFINIL CIV
Modafinilo
Modafinilo [Spanish]
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Nourypharma brand OF modafinil
Nuvigil
Provigil
Provigil®
R Modafinil
R-Modafinil
Sparlon
THN102 COMPONENT MODAFINIL
THN-102 COMPONENT MODAFINIL
Vigil
|
|
8 |
|
Esreboxetine |
Approved, Experimental, Investigational |
Phase 3 |
|
98769-81-4, 71620-89-8, 98819-76-2 |
65856 |
Synonyms:
(+)-(2S)-2-((S)-(2-Ethoxyphenoxy)phenylmethyl)morpholine
(S,S)-REBOXETINE
(SS)-Reboxetine
2-((2-Ethoxyphenoxy)benzyl)morpholine methanesulfonate
EDRONAX
Edronax®|PNU-165442G
|
Esreboxetine
PNU-165442G
Reboxetina
Reboxetine
Reboxetine mesylate
Vestra
|
|
9 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
10 |
|
Central Nervous System Stimulants |
|
Phase 3 |
|
|
|
11 |
|
Citrate |
|
Phase 3 |
|
|
|
12 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
13 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
14 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
15 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
16 |
|
Antidepressive Agents |
|
Phase 3 |
|
|
|
17 |
|
Flumazenil |
Approved |
Phase 1, Phase 2 |
|
78755-81-4 |
3373 |
Synonyms:
[<sup>11</sup>C]flumazenil (PET ligand)
Anexate
Anexate®|Ro15-1788
Anexic acid
FLUMAZENIL
Flumazenilo
Flumazenilum
Flumazepil
Hoffman la roche brand OF flumazenil
Hoffman-la roche brand OF flumazenil
|
Lanexat
MAZICON
RO15-1788
RO-151788
RO-15-1788
RO-151788000
RO-1722
RO-41-8157
Roche brand OF flumazenil
Romazicon
|
|
18 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Î’-imidazolyl-4-ethylamine
|
|
19 |
|
Dextroamphetamine |
Approved, Illicit, Investigational |
Phase 2 |
|
51-64-9, 300-62-9 |
5826 3007 |
Synonyms:
(±)-amphetamine|Amphetamine Sulfate®|DL-amphetamine
(+)-(S)-Amphetamine
(+)-alpha-Methylphenethylamine
(+)-alpha-Methylphenylethylamine
(+-)-alpha-Methylphenylethylamine
(+)-alpha-methylphenylethylamine|d-amphetamine|Dexadrine®|dextroamphetamine|Dextrostat®|S(+)amphetamine
(+)-a-Methylphenethylamine
(+)-a-Methylphenylethylamine
(+)-Amphetamine
(+)-phenaminum
(+)-Α-methylphenethylamine
(+)-Α-methylphenylethylamine
(+/-)-benzedrine
(+/-)-beta-phenylisopropylamine
(+/-)-desoxynorephedrine
(2S)-(+)-Amphetamine
(2S)-1-phenylpropan-2-amine
(AlphaS)-alpha-methylbenzeneethanamine
(AlphaS)-a-methylbenzeneethanamine
(AlphaS)-α-methylbenzeneethanamine
(S)-(+)-Amphetamine
(S)-(+)-beta-Phenylisopropylamine
(S)-(+)-b-Phenylisopropylamine
(S)-(+)-Î’-phenylisopropylamine
(S)-1-Phenyl-2-aminopropane
(S)-1-Phenyl-2-propanamine
(S)-1-Phenyl-2-propylamine
(S)-alpha-Methylbenzeneethanamine
(s)-alpha-methylphenethylamine
(s)-alpha-phenylethylamine
(S)-a-Methylbenzeneethanamine
(S)-Amphetamine
(S)-Α-methylbenzeneethanamine
(αS)-α-methylbenzeneethanamine
[1-(3-Methoxyphenyl)-2-propyl]amine
1-Methyl-2-phenylethylamine
1-Phenyl-2-aminopropane
3-Methoxy-a-methylbenzeneethanamine
3-Methoxyamphetamine
3-Methoxyphenylisopropylamine
Actedron
Adipan
Adzenys
ADZENYS ER
ADZENYS XR-ODT
Allodene
alpha-Methylbenzeneethaneamine
Amfetamin
Amfetamina
Amfetamine
Amfetaminum
Amphetamine
AMPHETAMINE RESIN COMPLEX
Amphetamine sulfate
Amphetamine sulfate (2:1)
Amsustain
Anorexide
Anorexine
Benzebar
Benzedrine
Benzolone
beta-Aminopropylbenzene
beta-Phenylisopropylamin
beta-Phenyl-isopropylamine
Celltech brand OF dextroamphetamine sulfate
Centramina
Curban
D Amphetamine
D Amphetamine sulfate
D-(+)-amphetamine
D-(s)-amphetamine
D-1-Phenyl-2-aminopropan
d-1-Phenyl-2-aminopropan [German]
D-1-Phenyl-2-aminopropane
D-2-Amino-1-phenylpropane
D-alpha-methylphenethylamine
D-am
D-Amphetamine
D-Amphetamine sulfate
Dephadren
Desamfetamina
Desoxyn
Desoxynorephedrin
Desoxynorephedrine
Dexacaps
Dexadrine
Dexamfetamina
|
Dexamfetamina [inn-spanish]
Dexamfetamine
Dexamfetaminum
Dexamfetaminum [inn-latin]
DEXAMPEX
Dexamphetamine
Dexamphetaminum [inn-latin]
Dexanfetamina
Dexanfetamina [inn-spanish]
Dexedrine
Dexedrine Spansule
Dexidrine
Dextro amphetamine
Dextro amphetamine sulfate
Dextroamphetamine
Dextro-amphetamine
DEXTROAMPHETAMINE RESIN COMPLEX
Dextroamphetamine sulfate
Dextro-amphetamine sulfate
DextroStat
DL-1-Phenyl-2-aminopropane
DL-alpha-Methylphenethylamine
DL-Amphetamine
DL-Benzedrine
Dyanavel
DYANAVEL XR
Elastonon
Fenamin
Fenamine
Fenylo-izopropylaminyl
FERNDEX
Finam
GlaxoSmithKline brand OF dextroamphetamine sulfate
Isoamycin
Isoamyne
Isomyn
L Amphetamine
L-Amphetamine
Levo amphetamine
Levoamphetamine
Levo-amphetamine
Mallinckrodt brand OF dextroamphetamine sulfate
Mecodrin
Methampex
Methamphetamine HCL
Miquel brand OF amfetamine sulfate
m-Methoxy-a-methylphenethylamine
m-Methoxyamphetamine
Mydrial
Norephedrane
Novydrine
NSC-27159
NSC-73713
Oktedrin
Ortedrine
Oxydess
Paredrine
Pasadena brand OF dextroamphetamine
Percomon
Phenamine
Phenedrine
Phenopromin
Phenylisopropylamine
Profamina
Propisamine
Psychedrine
rac-(2R)-1-phenylpropan-2-amine
rac-amphetamine
Raphetamine
Rhinalator
S(+)-amphetamine
Shire brand OF dextroamphetamine sulfate
Simpatedrin
Simpatina
Sulfate, amphetamine
Sulfate, dextroamphetamine
Sympamin
Sympamine
Sympatedrine
Thyramine
Vortech brand OF dextroamphetamine sulfate
Weckamine
α-methylbenzeneethaneamine
α-methylphenethylamine
β-aminopropylbenzene
β-phenylisopropylamine
|
|
20 |
|
Clarithromycin |
Approved |
Phase 2 |
|
81103-11-9 |
84029 |
Synonyms:
6-O-METHYL ERYTHROMYCIN
6-O-Methylerythromycin
6-O-Methylerythromycin a
A-56268
ABBOTT-56268
Biaxin
BIAXIN XL
BIAXIN XL PAC
CAM
CLA
CLARIE XL
CLARITHROMYCIN
CLARITHROMYCIN EXTENDED RELEASE
CLARITHROMYCIN IDENTITY
Clarithromycina
Clarithromycine
|
Clarithromycinum
Claritromicina
CLAROSIP
Clathromycin
FEBZIN XL
KLARICID
KLARICID 500
KLARICID ADULT
KLARICID I.V.
KLARICID PAED
KLARICID XL
MYCIFOR XL
PREVPAC
TE-031
XETININ XL
ZECLAR
|
|
21 |
|
Mazindol |
Approved, Investigational |
Phase 2 |
|
22232-71-9 |
4020 |
Synonyms:
[<sup>3</sup>H]-mazindol
42-548
AN-448
Diestet
Mazanor
Mazanor®|Sanorex®
MAZINDOL
MAZINDOL CIV
Mazindol medix brand
Mazindol novartis brand
Mazindol searle brand
Mazindol wyeth brand
Mazindole
|
MAZINDOLO
MAZINDOLUM
Medix brand OF mazindol
Novartis brand OF mazindol
SAH-42548
Sanjorex
Sanorex
Searle brand OF mazindol
Solucaps
Teronac
Teronak
Wyeth brand OF mazindol
|
|
22 |
|
Antidotes |
|
Phase 1, Phase 2 |
|
|
|
23 |
|
GABA Modulators |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
Protective Agents |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Histamine phosphate |
|
Phase 2 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
26 |
|
Adderall |
|
Phase 2 |
|
|
|
27 |
|
Sympathomimetics |
|
Phase 2 |
|
|
|
28 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
29 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
30 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
31 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
32 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 2 |
|
|
|
33 |
|
Dopamine Uptake Inhibitors |
|
Phase 2 |
|
|
|
34 |
|
Dopamine Agents |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 41)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation |
Completed |
NCT02637076 |
Phase 4 |
Xyrem |
2 |
A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. |
Completed |
NCT01800045 |
Phase 3 |
Pitolisant;Placebo |
3 |
A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy |
Completed |
NCT02720744 |
Phase 3 |
FT218;Placebo |
4 |
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy |
Completed |
NCT03030599 |
Phase 3 |
JZP-258 |
5 |
Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy |
Completed |
NCT01067235 |
Phase 3 |
BF2.649;BF2.649 add on Modafinil |
6 |
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy |
Completed |
NCT02221869 |
Phase 3 |
Xyrem |
7 |
Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy |
Completed |
NCT01067222 |
Phase 3 |
BF2.649;Modafinil;Placebo |
8 |
An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) |
Completed |
NCT01399606 |
Phase 3 |
BF2.649 |
9 |
A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy |
Recruiting |
NCT05059223 |
Phase 3 |
AXS-12 (reboxetine);Placebo |
10 |
Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period |
Active, not recruiting |
NCT02611687 |
Phase 3 |
pitolisant;Placebo |
11 |
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR |
Active, not recruiting |
NCT04451668 |
Phase 3 |
FT218 |
12 |
A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy |
Enrolling by invitation |
NCT05113745 |
Phase 3 |
AXS-12 (reboxetine);Placebo |
13 |
A Multi-center, Randomized, Double-blind, Placebo-controlled, 3-Week Crossover Study to Assess the Efficacy and Safety of AXS-12 in Subjects With Cataplexy and Excessive Daytime Sleepiness in Narcolepsy |
Completed |
NCT03881852 |
Phase 2 |
AXS-12 (Reboxetine);Placebo |
14 |
A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy |
Completed |
NCT04923594 |
Phase 2 |
mazindol extended release;Placebo |
15 |
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 |
Completed |
NCT02512588 |
Phase 2 |
BTD-001;Placebo |
16 |
A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors |
Completed |
NCT01183312 |
Phase 1, Phase 2 |
Flumazenil |
17 |
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy |
Recruiting |
NCT04072380 |
Phase 2 |
SUVN-G3031;Placebo |
18 |
Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines |
Recruiting |
NCT03772314 |
Phase 2 |
Modafinil;Amphetamine-Dextroamphetamine |
19 |
Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes |
Recruiting |
NCT04026958 |
Phase 2 |
Clarithromycin;Placebo |
20 |
A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy |
Enrolling by invitation |
NCT05055024 |
Phase 2 |
Mazindol |
21 |
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2) |
Terminated |
NCT04096560 |
Phase 2 |
TAK-994;Placebo |
22 |
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1) |
Terminated |
NCT04820842 |
Phase 2 |
TAK-994;Placebo |
23 |
A Double-blind, Placebo-controlled, Randomized, 3-period, 3-treatment Crossover Study to Evaluate the Effect of Multiple Oral Dose Administration of SEP-363856 in Male and Female Adult Subjects With Narcolepsy-cataplexy |
Completed |
NCT05015673 |
Phase 1 |
SEP363856;Placebo |
24 |
Single Center, Therapeutic Exploratory Clinical Trial to Evaluate the Safety of Sodium Oxybate (Xyrem) 500 mg/mL Oral Solution on Potential Endocrine Changes at Currently Labeled Therapeutic Dose Regimens (4.5 - 9 g/Day Divided Into Two Equal Doses) During 12 Weeks of Treatment of Cataplexy in Adult Patients With Narcolepsy. |
Completed |
NCT00345800 |
Phase 1 |
Sodium Oxybate (Xyrem) |
25 |
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects |
Completed |
NCT01093508 |
Phase 1 |
APD916 |
26 |
Microglial Activation in Narcolepsy Type 1 and Kleine-Levin Syndrome: Positron Emission Tomography (PET) Study in [18F] DPA-714 |
Unknown status |
NCT03754348 |
|
|
27 |
Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder |
Unknown status |
NCT03425214 |
|
|
28 |
The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol |
Completed |
NCT03356938 |
|
|
29 |
A Study to Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using a Portable Electroencephalogram Device |
Completed |
NCT04445129 |
|
|
30 |
Mind-Body Approach to Improve Health-Related Quality of Life for People With Narcolepsy |
Completed |
NCT04306952 |
|
|
31 |
A Placebo Control, Double Blind, Cross Over Study of Modafinil in Patients With Narcolepsy |
Completed |
NCT00174174 |
|
Modafinil |
32 |
Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia |
Completed |
NCT02913651 |
|
|
33 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168 |
|
|
34 |
Meditation-Relaxation (MR Therapy) for Sleep Paralysis: A Pilot Study in Patients With Narcolepsy |
Recruiting |
NCT04483310 |
|
|
35 |
Effectiveness of Group Psychotherapy in Patients With Narcolepsy Type 1 |
Recruiting |
NCT05314556 |
|
|
36 |
Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy |
Recruiting |
NCT05460052 |
|
|
37 |
Clinical and Neurophysiological Characteristics of Narcolepsy in Russia Basing on Clinical, Polysomnographic and Genome-wide Association Analyses of Narcolepsy With Cataplexy: a European Narcolepsy Network Study of 2013 |
Active, not recruiting |
NCT05375890 |
|
|
38 |
Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence |
Not yet recruiting |
NCT05615584 |
|
|
39 |
An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy |
No longer available |
NCT03433131 |
|
Pitolisant |
40 |
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy' |
Suspended |
NCT04419792 |
|
|
41 |
Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy |
Terminated |
NCT03198156 |
|
|
|